Seagen

Traded on the St. Petersburg Stock Exchange
Seagen is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Seagen was incorporated in 1997 and is headquartered in Bothell, Washington.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Seagen balance sheet

Report period2017 2018 2019 2020 2021 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Seagen cash flows

Report period2017 2018 2019 2020 2021 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Seagen multipliers

Report period2017 2018 2019 2020 2021 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Seagen profitability

Report period2017 2018 2019 2020 2021 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Seagen assets
Seagen cash flows

Seagen dividend policy

The company doesn't provide dividend
Seagen news
13.03.2023
Pfizer is buying biotech company Seagen for $43 billion, or $229 per share. Closing of deal is scheduled for late 2023 or early 2024.
Source: investors.pfizer.com pictogram investors.pfizer.com
Pictogram next
07.07.2022
Merck & Co. is in talks to buy Seagen, a biotech company that develops drugs to treat cancer, sources told the Wall Street Journal. Merck & Co. could pay about $40 billion, or more than $200 per Seagen share. The companies plan to close the deal before Merck announces its Q2 2022 financial results, due July 28.
Source: reuters.com pictogram reuters.com
Pictogram next
20.06.2022
Merck & Co. is in talks to buy biotech company Seagen, sources told the Wall Street Journal. Negotiations can result in both the purchase of the company and the conclusion of a marketing agreement.
Source: reuters.com pictogram reuters.com
Pictogram next
29.04.2022
Seagen's GAAP loss for 3 months of 2022 was $136.494 million, up 12.4% from $121.42 million in the prior year. Revenue increased 28.5% to $426.46 million from $331.983 million a year earlier.
Source: investor.seagen.com pictogram investor.seagen.com
Pictogram next
All Seagen news
General information
Company nameSeagen
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressBuilding 3 21717 30th Drive S.E Bothell, WA 98021 United States
Mailing addressBuilding 3 21717 30th Drive S.E Bothell, WA 98021 United States
Websiteinvestor.seagen.com
Information disclosurewww.sec.gov